Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Hsu, Hsao Hsun ^a   Ko, Wen Je ^a   Hsu, Jo Yu ^a   Chen, Jin Shing ^a   Lee, Yung Chie ^a   Lai, I Rue ^a   Chen, Chau Fong ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE; HEME OXYGENASE 1; MONOCROTALINE; SIMVASTATIN; HMOX1 PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG; LUNG ARTERY PRESSURE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; WESTERN BLOTTING; ANIMAL; METABOLISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; FEMALE; HEME OXYGENASE (DECYCLIZING); HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SIMVASTATIN; TREATMENT OUTCOME;

EID: 66649123242     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-32     Document Type: Article

References (47)

1. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 1995, 47(1):87-131.
2. Ganesh SK, Nass CM, Blumenthal RS. Anti-atherosclerotic effects of statins: lessons from prevention trials. J Cardiovasc Risk 2003, 10(3):155-159. 10.1097/00043798-200306000-00002, 12775947.
3. LaRosa JC. Statins and risk of coronary heart disease. JAMA 2000, 283(22):2935-2936. 10.1001/jama.283.22.2935, 10865268.
4. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 1996, 347(8994):102-103. 10.1016/S0140-6736(96)90217-2, 8538301.
5. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003, 99(1):95-112. 10.1016/S0163-7258(03)00055-X, 12804701.
6. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007, 4(6):319-329. 10.1038/ncpcardio0890, 17522721.
7. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006, 291(4):L668-676. 10.1152/ajplung.00491.2005, 16698853.
8. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007, 292(5):L1105-1110. 10.1152/ajplung.00411.2006, 17277047.
9. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002, 166(10):1403-1408. 10.1164/rccm.200203-268OC, 12406854.
10. Vitali SH, Mitsialis SA, Christou H, Fernandez G, Angeles, Liu X, Kourembanas S. Mechanisms of Heme Oxygenase-1-Mediated Cardiac and Pulmonary Vascular Protection in Chronic Hypoxia: Roles of Carbon Monoxide and Bilirubin. Chest 2005, 128(6_suppl):578S-579. 10.1378/chest.128.6_suppl.578S, 16373841.
11. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988, 2(10):2557-2568.
12. Morse D, Choi AM. Heme oxygenase-1: from bench to bedside. Am J Respir Crit Care Med 2005, 172(6):660-670. 10.1164/rccm.200404-465SO, 15901614.
13. Christou H, Morita T, Hsieh CM, Koike H, Arkonac B, Perrella MA, Kourembanas S. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Circ Res 2000, 86(12):1224-1229.
14. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 2001, 98(15):8798-8803. 37515, 11447290, 10.1073/pnas.161272598.
15. Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schurger S, Wijayanti N, Immenschuh S, Schroder H. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004, 37(12):2064-2071. 10.1016/j.freeradbiomed.2004.09.009, 15544924.
16. Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004, 110(10):1296-1302. 10.1161/01.CIR.0000140694.67251.9C, 15337692.
17. Lai IR, Chang KJ, Tsai HW, Chen CF. Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Transplantation 2008, 85(5):732-738. 10.1097/TP.0b013e3181664e70, 18337668.
18. Lai YL, Wu HD, Chen CF. Antioxidants attenuate chronic hypoxic pulmonary hypertension. J Cardiovasc Pharmacol 1998, 32(5):714-720. 10.1097/00005344-199811000-00006, 9821844.
19. Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol 1996, 270(1 Pt 2):H107-114.
20. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968, 61(2):748-755. 225223, 4386763, 10.1073/pnas.61.2.748.
21. McNally SJ, Ross JA, James Garden O, Wigmore SJ. Optimization of the paired enzyme assay for heme oxygenase activity. Anal Biochem 2004, 332(2):398-400. 10.1016/j.ab.2004.06.024, 15325310.
22. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(1 Suppl):7S-10S. 10.1378/chest.126.1_suppl.7S, 15249491.
23. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero ML. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994, 89(4):1733-1744.
24. Micah R. Fisher SCMHCCREGTH-HLHJAKFWPMH: Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis & Rheumatism 2006, 54(9):3043-3050.
25. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective Tissue Disease-associated Pulmonary Arterial Hypertension in the Modern Treatment Era. Am J Respir Crit Care Med 2009, 179(2):151-157. 10.1164/rccm.200806-953OC, 18931333.
26. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003, 108(13):1640-1645. 10.1161/01.CIR.0000087592.47401.37, 12963647.
27. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicology and Applied Pharmacology 1990, 106(2):179-200.
28. Stenmark KR, Morganroth ML, Remigio LK, Voelkel NF, Murphy RC, Henson PM, Mathias MM, Reeves JT. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol 1985, 248(6 Pt 2):H859-H866. 3923843.
29. Roth RA, Ganey PE. Platelets and the puzzles of pulmonary pyrrolizidine poisoning. Toxicology and Applied Pharmacology 1988, 93(3):463-471.
30. Yu CC, Lai YL. Chronic hypoxia attenuates ischemia-reperfusion-induced increase in pulmonary vascular resistance. Life Sci 2003, 73(17):2171-2184. 10.1016/S0024-3205(03)00601-5, 12927588.
31. Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA. Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. Am J Physiol 1999, 276(3 Pt 1):L443-L451. 10070108.
32. Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996, 15:9-19. 8679227.
33. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006, 99(7):675-691. 10.1161/01.RES.0000243584.45145.3f, 17008597.
34. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997, 272(50):31725-31729. 10.1074/jbc.272.50.31725, 9395516.
35. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003, 285(3):H938-945.
36. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997, 272(9):5375-5381. 10.1074/jbc.272.49.30998, 9038135.
37. Morita T, Perrella MA, Lee ME, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci USA 1995, 92(5):1475-1479. 42542, 7878003, 10.1073/pnas.92.5.1475.
38. Hartsfield CL, Alam J, Cook JL, Choi AM. Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide. Am J Physiol 1997, 273(5 Pt 1):L980-988.
39. Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Expression of heme oxygenase-1 in the lung in chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 278(4):L806-812.
40. Fredenburgh LE, Perrella MA, Mitsialis SA. The role of heme oxygenase-1 in pulmonary disease. Am J Respir Cell Mol Biol 2007, 36(2):158-165. 2176110, 16980551, 10.1165/rcmb.2006-0331TR.
41. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 1999, 103(8):R23-29. 408281, 10207174, 10.1172/JCI6163.
42. Goto J, Ishikawa K, Kawamura K, Watanabe Y, Matumoto H, Sugawara D, Maruyama Y. Heme oxygenase-1 reduces murine monocrotaline-induced pulmonary inflammatory responses and resultant right ventricular overload. Antioxid Redox Signal 2002, 4(4):563-568. 10.1089/15230860260220058, 12230867.
43. Girgis RE, Ma SF, Ye S, Grigoryev DN, Li D, Hassoun PM, Tuder RM, Johns RA, Garcia JG. Differential gene expression in chronic hypoxic pulmonary hypertension: effect of simvastatin treatment. Chest 2005, 128(6 Suppl):579S. 10.1378/chest.128.6_suppl.579S, 16373842.
44. Zhou H, Liu H, Porvasnik SL, Terada N, Agarwal A, Cheng Y, Visner GA. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 2006, 86(1):62-71. 10.1038/labinvest.3700361, 16357868.
45. Smith A, Alam J, Escriba PV, Morgan WT. Regulation of heme oxygenase and metallothionein gene expression by the heme analogs, cobalt-, and tin-protoporphyrin. J Biol Chem 1993, 268(10):7365-7371.
46. Breslow E, Chandra R, Kappas A. Biochemical properties of the heme oxygenase inhibitor, Sn-protoporphyrin. Interactions with apomyoglobin and human serum albumin. J Biol Chem 1986, 261(7):3135-3141.
47. Sardana MK, Kappas A. Dual control mechanism for heme oxygenase: tin (IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proceedings of the National Academy of Sciences of the United States of America 1987, 84(8):2464. 304672, 3470805, 10.1073/pnas.84.8.2464.